Entry Point Capital, LLC Terns Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
3 transactions
Others Institutions Holding TERN
# of Institutions
167Shares Held
78.3MCall Options Held
580KPut Options Held
454K-
Orbimed Advisors LLC San Diego, CA7.56MShares$44.3 Million1.49% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$40.4 Million8.42% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT6.22MShares$36.5 Million4.41% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$32.7 Million1.71% of portfolio
-
Black Rock Inc. New York, NY4.12MShares$24.1 Million0.0% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $220M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...